pembrolizumab

You have access
Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy
YUDAI ISHIYAMA, TSUNENORI KONDO, YUKI NEMOTO, YUKI KOBARI, HIROKI ISHIHARA, HIDEKAZU TACHIBANA, KAZUHIKO YOSHIDA, YASUNOBU HASHIMOTO, TOSHIO TAKAGI, JUNPEI IIZUKA and KAZUNARI TANABE

Anticancer Research March 2021, 41 (3) 1607-1614; DOI: https://doi.org/10.21873/anticanres.14922
You have access
Complete Response of Bone Metastasis in Non-small Cell Lung Cancer With Pembrolizumab: Two Case Reports
YOHEI ASANO, NORIO YAMAMOTO, KATSUHIRO HAYASHI, AKIHIKO TAKEUCHI, SHINJI MIWA, KENTARO IGARASHI, HIROTAKA YONEZAWA, YOSHIHIRO ARAKI, SEI MORINAGA, KAZUO KASAHARA, TAKASHI SONE and HIROYUKI TSUCHIYA

Anticancer Research March 2021, 41 (3) 1693-1699; DOI: https://doi.org/10.21873/anticanres.14933
You have access
Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma
JANICE B. HU, SURYA RAVICHANDRAN, CHRISTEL RUSHING, GEORGIA M. BEASLEY, BRENT A. HANKS, SIN-HO JUNG, APRIL K.S. SALAMA, LISA HO and PAUL J. MOSCA

Anticancer Research September 2020, 40 (9) 5245-5254; DOI: https://doi.org/10.21873/anticanres.14528
You have access
Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report
MASASHI NAKAMURA, MASAKI UENO, SHINYA HAYAMI, MANABU KAWAI, ATSUSHI MIYAMOTO, NORIHIKO SUZAKI, SEIKO HIRONO, KEN-ICHI OKADA, MOTOKI MIYAZAWA, YUJI KITAHATA, RYOHEI KOBAYASHI, FUMIYOSHI KOJIMA and HIROKI YAMAUE

Anticancer Research July 2020, 40 (7) 4123-4129; DOI: https://doi.org/10.21873/anticanres.14411
You have access
Pembrolizumab and Radiotherapy for Platinum-refractory Recurrent Uterine Carcinosarcoma With an Abscopal Effect: A Case Report
MITSUTAKE YANO, SAKI ASO, MIHO SATO, YOKO AOYAGI, HARUNOBU MATSUMOTO and KAEI NASU

Anticancer Research July 2020, 40 (7) 4131-4135; DOI: https://doi.org/10.21873/anticanres.14412
You have access
Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab
LUKA SIMETIĆ, KREŠIMIR BLAŽIČEVIĆ, KATA MEĐUGORAC, MARIN GOLČIĆ and DAVORIN HERCEG

Anticancer Research April 2020, 40 (4) 2157-2163; DOI: https://doi.org/10.21873/anticanres.14175
You have access
Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer
TSUKASA HASEGAWA, NORIKO YANAGITANI, HIROFUMI UTSUMI, HIROSHI WAKUI, HIROAKI SAKAMOTO, TAKEHIRO TOZUKA, HIROSHI YOSHIDA, YOSHIAKI AMINO, SHINYA UEMATSU, TAKAHIRO YOSHIZAWA, KEN UCHIBORI, SATORU KITAZONO, ATSUSHI HORIIKE, TAKESHI HORAI, KAZUYOSHI KUWANO and MAKOTO NISHIO

Anticancer Research December 2019, 39 (12) 6851-6857; DOI: https://doi.org/10.21873/anticanres.13902
You have access
Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma
AGATA MARJANSKA, PRZEMYSLAW GALAZKA, MICHAL MARJANSKI, MARIUSZ WYSOCKI and JAN STYCZYNSKI

Anticancer Research July 2019, 39 (7) 3945-3947; DOI: https://doi.org/10.21873/anticanres.13547
You have access
Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors
JACOPO GIULIANI and ANDREA BONETTI

Anticancer Research July 2019, 39 (7) 3961-3965; DOI: https://doi.org/10.21873/anticanres.13550
You have access
Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer
SHOTARO YASUOKA, TAKESHI YUASA, NORIKO NISHIMURA, MASAHIRO OGAWA, YOSHINOBU KOMAI, NOBORU NUMAO, SHINYA YAMAMOTO, YUKIHIRO KONDO and JUNJI YONESE

Anticancer Research July 2019, 39 (7) 3887-3892; DOI: https://doi.org/10.21873/anticanres.13539

Main menu

User menu

Search

pembrolizumab

Pages